新辅助治疗后胰腺导管腺癌根治性切除后极早期复发的预后因素
本研究基于两个机构数据库,纳入305例新辅助治疗后行根治性切除的胰腺导管腺癌患者,其中28例(9.1%)在术后3个月内复发。多因素回归显示淋巴结阳性与极早期复发独立相关(OR 2.57,95%CI 1.15-5.8),而R状态、新辅助治疗方案类型及术前CA19-9水平未显示关联。极早期复发患者中位总生存仅6个月,显著劣于其余患者的40个月(P<.0001)。
要点
- 淋巴结阳性是新辅助治疗后极早期复发的独立预后因素。
- 极早期复发患者中位总生存仅6个月,需密切随访。
- R状态、新辅助方案类型及术前CA19-9与极早期复发无关。
核心结论
- 淋巴结阳性是新辅助治疗后极早期复发的独立预后标志物,提示这类患者需更密切随访并可能受益于额外或早期启动的辅助治疗。
研究设计与样本
- 回顾性队列研究,从两个机构数据库中筛选新辅助治疗后行根治性切除的胰腺导管腺癌患者,排除术后90天内死亡及CA19-9不分泌者后纳入305例。
主要发现
- 28例(9.1%)患者出现术后≤3个月的复发。
- 极早期复发患者中位总生存为6个月(95%CI 5-32个月),其余患者为40个月(95%CI 32-60个月),P<.0001。
- 多因素回归中淋巴结阳性与极早期复发相关(OR 2.57,95%CI 1.15-5.8)。
- R状态、新辅助治疗类型及术前CA19-9水平与极早期复发无关联。
临床怎么用
- 对淋巴结阳性的新辅助治疗后切除患者应加强术后随访监测。
- 可考虑对这类高危患者额外或早期启动辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Very early recurrence in pancreatic ductal adenocarcinoma has been defined as recurrence ≤3 months after resection. Besides others, neoadjuvant treatment is delivered based on the assumption of preoperative eradication of micrometastasis as well as local downstaging. Prognostic factors of very early recurrence after neoadjuvant treatment remain largely unexplored. METHODS: All patients who underwent resection for pancreatic ductal adenocarcinoma after neoadjuvant treatment were identified from 2 institutional databases. Clinicopathologic data and demographics were extracted. Univariable and multivariable logistic regression modeling was performed. Multicollinearity was assessed with a variance inflation factor. RESULTS: After excluding patients who died within 90 days postresection and CA19-9 nonsecretors, 305 patients remained. A total of 178 (58.4%) patients received FOLFIRINOX, 39 (12.8%) received gemcitabine-based neoadjuvant treatment and 88 (28.9%) received various combinations. Pancreatic head resection was performed in 240 (78.7%) patients, whereas 65 (21.3%) underwent distal or total pancreatectomy. In total, 28 (9.1%) patients experienced recurrence ≤3 months. Median overall survival was 6 months (95% confidence interval: 5-32 months) in patients with very early recurrence, compared with 40 months (95% confidence interval: 32-60 months) in the remaining cohort (P < .0001). In multivariable regression analysis, positive lymph node status was associated with very early recurrence (odds ratio: 2.57, 95% confidence interval: 1.15-5.8). Notably, no association with R status, type of neoadjuvant treatment, or preoperative CA19-9 levels was detected. CONCLUSION: Positive lymph node status is an independent prognostic marker for very early recurrence after neoadjuvant treatment, indicating that these patients require closer follow-up and may benefit from additional or early initiation of adjuvant therapy.
引用
- Leonhardt CS, Narbekovas K, Qadan M, et al. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Surgery. 2025. PMID: 40913806. doi:10.1016/j.surg.2025.109647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。